ERBB receptors: From oncogene discovery to basic science to mechanism-based cancer therapeutics

Cancer Cell

Volumn 25, Issue 3, 2014, Pages 282-303

  Arteaga, Carlos L ^a   Engelman, Jeffrey A ^b  

^a VANDERBILT INGRAM CANCER CENTER   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEOPLASM; PRIORITY JOURNAL; REVIEW;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; DRUG RESISTANCE, NEOPLASM; HUMANS; MICE; NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECEPTOR, ERBB-3; SIGNAL TRANSDUCTION;

EID: 84896091512     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccr.2014.02.025     Document Type: Review

References (222)

1. Agus D.B., Akita R.W., Fox W.D., Lewis G.D., Higgins B., Pisacane P.I., Lofgren J.A., Tindell C., Evans D.P., Maiese K., et al. Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell 2002, 2:127-137.
2. Andrechek E.R., Hardy W.R., Siegel P.M., Rudnicki M.A., Cardiff R.D., Muller W.J. Amplification of the neu/erbB-2 oncogene in a mouse model of mammary tumorigenesis. Proc. Natl. Acad. Sci. USA 2000, 97:3444-3449.
3. Anido J., Scaltriti M., Bech Serra J.J., Santiago Josefat B., Todo F.R., Baselga J., Arribas J. Biosynthesis of tumorigenic HER2 C-terminal fragments by alternative initiation of translation. EMBO J. 2006, 25:3234-3244.
4. Avraham R., Yarden Y. Feedback regulation of EGFR signalling: decision making by early and delayed loops. Nat. Rev. Mol. Cell Biol. 2011, 12:104-117.
5. Balko J.M., Cook R.S., Vaught D.B., Kuba M.G., Miller T.W., Bhola N.E., Sanders M.E., Granja-Ingram N.M., Smith J.J., Meszoely I.M., et al. Profiling of residual breast cancers after neoadjuvant chemotherapy identifies DUSP4 deficiency as a mechanism of drug resistance. Nat. Med. 2012, 18:1052-1059.
6. Balko J.M., Giltnane J.M., Wang K., Schwarz L.J., Young C.D., Cook R.S., Owens P., Sanders M.E., Kuba M.G., Sánchez V., et al. Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets. Cancer Discov. 2014, 4:232-245.
7. Bang Y.J., Van Cutsem E., Feyereislova A., Chung H.C., Shen L., Sawaki A., Lordick F., Ohtsu A., Omuro Y., Satoh T., et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010, 376:687-697. ToGA Trial Investigators.
8. Bardia A., Baselga J. Neoadjuvant therapy as a platform for drug development and approval in breast cancer. Clin. Cancer Res. 2013, 19:6360-6370.
9. Baselga J., Bradbury I., Eidtmann H., Di Cosimo S., de Azambuja E., Aura C., Gómez H., Dinh P., Fauria K., Van Dooren V., et al. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet 2012, 379:633-640. NeoALTTO Study Team.
10. Baselga J., Cortés J., Kim S.B., Im S.A., Hegg R., Im Y.H., Roman L., Pedrini J.L., Pienkowski T., Knott A., et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N.Engl. J. Med. 2012, 366:109-119. CLEOPATRA Study Group.
11. Baselga, J., Majewski, I., Nuciforo, P., Eidtmann, H., Holmes, E., Sotiriou, C., Fumagalli, D., Diaz Delgado, M.C., Piccart-Gebhart, M., and Bernards, R. (2013a). PIK3CA mutations and correlation with pCR in the NeoALTTO trial (BIG 01-06). European Cancer Congress 2013.
12. Baselga J., Verma S., Ro J., Huober J., Guardino E., Fang L., Olsen S., Lewis Phillips G., de Haas S., Pegram M. Relationship between tumor biomarkers (BM) and efficacy in EMILIA, a phase III study of trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer (MBC). Cancer Res. 2013, 73(Suppl.). LB-63.
13. Bean J., Brennan C., Shih J.Y., Riely G., Viale A., Wang L., Chitale D., Motoi N., Szoke J., Broderick S., et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc. Natl. Acad. Sci. USA 2007, 104:20932-20937.
14. Berns K., Horlings H.M., Hennessy B.T., Madiredjo M., Hijmans E.M., Beelen K., Linn S.C., Gonzalez-Angulo A.M., Stemke-Hale K., Hauptmann M., et al. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 2007, 12:395-402.
15. Bertotti A., Migliardi G., Galimi F., Sassi F., Torti D., Isella C., Corà D., Di Nicolantonio F., Buscarino M., Petti C., et al. A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. Cancer Discov. 2011, 1:508-523.
16. Blackwell K.L., Burstein H.J., Storniolo A.M., Rugo H., Sledge G., Koehler M., Ellis C., Casey M., Vukelja S., Bischoff J., et al. Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J.Clin. Oncol. 2010, 28:1124-1130.
17. Bonner J.A., Harari P.M., Giralt J., Azarnia N., Shin D.M., Cohen R.B., Jones C.U., Sur R., Raben D., Jassem J., et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N.Engl. J. Med. 2006, 354:567-578.
18. Bose R., Kavuri S.M., Searleman A.C., Shen W., Shen D., Koboldt D.C., Monsey J., Goel N., Aronson A.B., Li S., et al. Activating HER2 mutations in HER2 gene amplification negative breast cancer. Cancer Discov. 2013, 3:224-237.
19. Burstein H.J., Sun Y., Dirix L.Y., Jiang Z., Paridaens R., Tan A.R., Awada A., Ranade A., Jiao S., Schwartz G., et al. Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer. J.Clin. Oncol. 2010, 28:1301-1307.
20. Burtness B., Goldwasser M.A., Flood W., Mattar B., Forastiere A.A. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J.Clin. Oncol. 2005, 23:8646-8654. Eastern Cooperative Oncology Group.
21. Comprehensive molecular portraits of human breast tumours. Nature 2012, 490:61-70. Cancer Genome Atlas Network.
22. Cappuzzo F., Varella-Garcia M., Shigematsu H., Domenichini I., Bartolini S., Ceresoli G.L., Rossi E., Ludovini V., Gregorc V., Toschi L., et al. Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients. J.Clin. Oncol. 2005, 23:5007-5018.
23. Carey K.D., Garton A.J., Romero M.S., Kahler J., Thomson S., Ross S., Park F., Haley J.D., Gibson N., Sliwkowski M.X. Kinetic analysis of epidermal growth factor receptor somatic mutant proteins shows increased sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib. Cancer Res. 2006, 66:8163-8171.
24. Chakrabarty A., Rexer B.N., Wang S.E., Cook R.S., Engelman J.A., Arteaga C.L. H1047R phosphatidylinositol 3-kinase mutant enhances HER2-mediated transformation by heregulin production and activation of HER3. Oncogene 2010, 29:5193-5203.
25. Chakrabarty A., Sánchez V., Kuba M.G., Rinehart C., Arteaga C.L. Feedback upregulation of HER3 (ErbB3) expression and activity attenuates antitumor effect of PI3K inhibitors. Proc. Natl. Acad. Sci. USA 2012, 109:2718-2723.
26. Chakrabarty A., Bhola N.E., Sutton C., Ghosh R., Kuba M.G., Dave B., Chang J.C., Arteaga C.L. Trastuzumab-resistant cells rely on a HER2-PI3K-FoxO-survivin axis and are sensitive to PI3K inhibitors. Cancer Res. 2013, 73:1190-1200.
27. Chandarlapaty S., Sawai A., Scaltriti M., Rodrik-Outmezguine V., Grbovic-Huezo O., Serra V., Majumder P.K., Baselga J., Rosen N. AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity. Cancer Cell 2011, 19:58-71.
28. Cho H.S., Mason K., Ramyar K.X., Stanley A.M., Gabelli S.B., Denney D.W., Leahy D.J. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature 2003, 421:756-760.
29. Clynes R.A., Towers T.L., Presta L.G., Ravetch J.V. Inhibitory Fc receptors modulate invivo cytotoxicity against tumor targets. Nat. Med. 2000, 6:443-446.
30. Cook R.S., Garrett J.T., Sánchez V., Stanford J.C., Young C., Chakrabarty A., Rinehart C., Zhang Y., Wu Y., Greenberger L., et al. ErbB3 ablation impairs phosphatidylinositol 3-kinase (PI3K)/AKT-dependent mammary tumorigenesis. Cancer Res. 2011, 71:3941-3951.
31. Corcoran R.B., Ebi H., Turke A.B., Coffee E.M., Nishino M., Cogdill A.P., Brown R.D., Della Pelle P., Dias-Santagata D., Hung K.E., et al. EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. Cancer Discov. 2012, 2:227-235.
32. Cortot A.B., Repellin C.E., Shimamura T., Capelletti M., Zejnullahu K., Ercan D., Christensen J.G., Wong K.K., Gray N.S., Jänne P.A. Resistance to irreversible EGF receptor tyrosine kinase inhibitors through a multistep mechanism involving the IGF1R pathway. Cancer Res. 2013, 73:834-843.
33. Cunningham D., Humblet Y., Siena S., Khayat D., Bleiberg H., Santoro A., Bets D., Mueser M., Harstrick A., Verslype C., et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N.Engl. J. Med. 2004, 351:337-345.
34. Dave B., Migliaccio I., Gutierrez M.C., Wu M.F., Chamness G.C., Wong H., Narasanna A., Chakrabarty A., Hilsenbeck S.G., Huang J., et al. Loss of phosphatase and tensin homolog or phosphoinositol-3 kinase activation and response to trastuzumab or lapatinib in human epidermal growth factor receptor 2-overexpressing locally advanced breast cancers. J.Clin. Oncol. 2011, 29:166-173.
35. Diaz L.A., Williams R.T., Wu J., Kinde I., Hecht J.R., Berlin J., Allen B., Bozic I., Reiter J.G., Nowak M.A., et al. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature 2012, 486:537-540.
36. Ding L., Getz G., Wheeler D.A., Mardis E.R., McLellan M.D., Cibulskis K., Sougnez C., Greulich H., Muzny D.M., Morgan M.B., et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 2008, 455:1069-1075.
37. Douillard J.Y., Zemelka T., Fountzilas G., Barone C., Schlichting M., Heighway J., Eggleton S.P., Srimuninnimit V. FOLFOX4 With Cetuximab vs. UFOX With Cetuximab as First-Line Therapy in Metastatic Colorectal Cancer: The Randomized Phase II FUTURE Study. Clin. Colorectal Cancer 2014, 13. 14-26.e1.
38. Downward J., Yarden Y., Mayes E., Scrace G., Totty N., Stockwell P., Ullrich A., Schlessinger J., Waterfield M.D. Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences. Nature 1984, 307:521-527.
39. Ebi H., Corcoran R.B., Singh A., Chen Z., Song Y., Lifshits E., Ryan D.P., Meyerhardt J.A., Benes C., Settleman J., et al. Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers. J.Clin. Invest. 2011, 121:4311-4321.
40. Eichhorn P.J., Gili M., Scaltriti M., Serra V., Guzman M., Nijkamp W., Beijersbergen R.L., Valero V., Seoane J., Bernards R., Baselga J. Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235. Cancer Res. 2008, 68:9221-9230.
41. Engelman J.A. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat. Rev. Cancer 2009, 9:550-562.
42. Engelman J.A., Jänne P.A., Mermel C., Pearlberg J., Mukohara T., Fleet C., Cichowski K., Johnson B.E., Cantley L.C. ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines. Proc. Natl. Acad. Sci. USA 2005, 102:3788-3793.
43. Engelman J.A., Mukohara T., Zejnullahu K., Lifshits E., Borrás A.M., Gale C.M., Naumov G.N., Yeap B.Y., Jarrell E., Sun J., et al. Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer. J.Clin. Invest. 2006, 116:2695-2706.
44. Engelman J.A., Zejnullahu K., Mitsudomi T., Song Y., Hyland C., Park J.O., Lindeman N., Gale C.M., Zhao X., Christensen J., et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007, 316:1039-1043.
45. Ercan D., Xu C., Yanagita M., Monast C.S., Pratilas C.A., Montero J., Butaney M., Shimamura T., Sholl L., Ivanova E.V., et al. Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors. Cancer Discov. 2012, 2:934-947.
46. Esteva F.J., Guo H., Zhang S., Santa-Maria C., Stone S., Lanchbury J.S., Sahin A.A., Hortobagyi G.N., Yu D. PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer. Am. J. Pathol. 2010, 177:1647-1656.
47. Faber A.C., Wong K.K., Engelman J.A. Differences underlying EGFR and HER2 oncogene addiction. Cell Cycle 2010, 9:851-852.
48. Faber A.C., Corcoran R.B., Ebi H., Sequist L.V., Waltman B.A., Chung E., Incio J., Digumarthy S.R., Pollack S.F., Song Y., et al. BIM expression in treatment-naive cancers predicts responsiveness to kinase inhibitors. Cancer Discov. 2011, 1:352-365.
49. Fan Z., Lu Y., Wu X., Mendelsohn J. Antibody-induced epidermal growth factor receptor dimerization mediates inhibition of autocrine proliferation of A431 squamous carcinoma cells. J.Biol. Chem. 1994, 269:27595-27602.
50. Finkle D., Quan Z.R., Asghari V., Kloss J., Ghaboosi N., Mai E., Wong W.L., Hollingshead P., Schwall R., Koeppen H., Erickson S. HER2-targeted therapy reduces incidence and progression of midlife mammary tumors in female murine mammary tumor virus huHER2-transgenic mice. Clin. Cancer Res. 2004, 10:2499-2511.
51. Franklin M.C., Carey K.D., Vajdos F.F., Leahy D.J., de Vos A.M., Sliwkowski M.X. Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell 2004, 5:317-328.
52. Frederick L., Wang X.Y., Eley G., James C.D. Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas. Cancer Res. 2000, 60:1383-1387.
53. Gandhi L., Bahleda R., Tolaney S.M., Kwak E.L., Cleary J.M., Pandya S.S., Hollebecque A., Abbas R., Ananthakrishnan R., Berkenblit A., et al. Phase I study of neratinib in combination with temsirolimus in patients with human epidermal growth factor receptor 2-dependent and other solid tumors. J.Clin. Oncol. 2014, 32:68-75.
54. Garner A.P., Bialucha C.U., Sprague E.R., Garrett J.T., Sheng Q., Li S., Sineshchekova O., Saxena P., Sutton C.R., Chen D., et al. An antibody that locks HER3 in the inactive conformation inhibits tumor growth driven by HER2 or neuregulin. Cancer Res. 2013, 73:6024-6035.
55. Garrett T.P., McKern N.M., Lou M., Elleman T.C., Adams T.E., Lovrecz G.O., Kofler M., Jorissen R.N., Nice E.C., Burgess A.W., Ward C.W. The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation, poised to interact with other ErbB receptors. Mol. Cell 2003, 11:495-505.
56. Garrett J.T., Olivares M.G., Rinehart C., Granja-Ingram N.D., Sánchez V., Chakrabarty A., Dave B., Cook R.S., Pao W., McKinely E., et al. Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase. Proc. Natl. Acad. Sci. USA 2011, 108:5021-5026.
57. Garrett J.T., Sutton C.R., Kuba M.G., Cook R.S., Arteaga C.L. Dual blockade of HER2 in HER2-overexpressing tumor cells does not completely eliminate HER3 function. Clin. Cancer Res. 2013, 19:610-619.
58. Garrett J.T., Sutton C.R., Kurupi R., Bialucha C.U., Ettenberg S.A., Collins S.D., Sheng Q., Wallweber J., Defazio-Eli L., Arteaga C.L. Combination of antibody that inhibits ligand-independent HER3 dimerization and a p110α inhibitor potently blocks PI3K signaling and growth of HER2+ breast cancers. Cancer Res. 2013, 73:6013-6023.
59. Gennari R., Menard S., Fagnoni F., Ponchio L., Scelsi M., Tagliabue E., Castiglioni F., Villani L., Magalotti C., Gibelli N., et al. Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2. Clin. Cancer Res. 2004, 10:5650-5655.
60. Geyer C.E., Forster J., Lindquist D., Chan S., Romieu C.G., Pienkowski T., Jagiello-Gruszfeld A., Crown J., Chan A., Kaufman B., et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N.Engl. J. Med. 2006, 355:2733-2743.
61. Ghosh R., Narasanna A., Wang S.E., Liu S., Chakrabarty A., Balko J.M., González-Angulo A.M., Mills G.B., Penuel E., Winslow J., et al. Trastuzumab has preferential activity against breast cancers driven by HER2 homodimers. Cancer Res. 2011, 71:1871-1882.
62. Gianni L., Eiermann W., Semiglazov V., Manikhas A., Lluch A., Tjulandin S., Zambetti M., Vazquez F., Byakhow M., Lichinitser M., et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet 2010, 375:377-384.
63. Gianni L., Pienkowski T., Im Y.H., Roman L., Tseng L.M., Liu M.C., Lluch A., Staroslawska E., de la Haba-Rodriguez J., Im S.A., et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol. 2012, 13:25-32.
64. Gilbertson R., Hernan R., Pietsch T., Pinto L., Scotting P., Allibone R., Ellison D., Perry R., Pearson A., Lunec J. Novel ERBB4 juxtamembrane splice variants are frequently expressed in childhood medulloblastoma. Genes Chromosomes Cancer 2001, 31:288-294.
65. Goldberg S.B., Supko J.G., Neal J.W., Muzikansky A., Digumarthy S., Fidias P., Temel J.S., Heist R.S., Shaw A.T., McCarthy P.O., et al. A phase I study of erlotinib and hydroxychloroquine in advanced non-small-cell lung cancer. J.Thorac. Oncol. 2012, 7:1602-1608.
66. Greulich H., Chen T.H., Feng W., Jänne P.A., Alvarez J.V., Zappaterra M., Bulmer S.E., Frank D.A., Hahn W.C., Sellers W.R., Meyerson M. Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants. PLoS Med. 2005, 2:e313.
67. Guix M., Faber A.C., Wang S.E., Olivares M.G., Song Y., Qu S., Rinehart C., Seidel B., Yee D., Arteaga C.L., Engelman J.A. Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins. J.Clin. Invest. 2008, 118:2609-2619.
68. Haas-Kogan D.A., Prados M.D., Tihan T., Eberhard D.A., Jelluma N., Arvold N.D., Baumber R., Lamborn K.R., Kapadia A., Malec M., et al. Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib. J.Natl. Cancer Inst. 2005, 97:880-887.
69. Hanker A.B., Pfefferle A.D., Balko J.M., Kuba M.G., Young C.D., Sánchez V., Sutton C.R., Cheng H., Perou C.M., Zhao J.J., et al. Mutant PIK3CA accelerates HER2-driven transgenic mammary tumors and induces resistance to combinations of anti-HER2 therapies. Proc. Natl. Acad. Sci. USA 2013, 110:14372-14377.
70. Harris L.N., You F., Schnitt S.J., Witkiewicz A., Lu X., Sgroi D., Ryan P.D., Come S.E., Burstein H.J., Lesnikoski B.A., et al. Predictors of resistance to preoperative trastuzumab and vinorelbine for HER2-positive early breast cancer. Clin. Cancer Res. 2007, 13:1198-1207.
71. Hegde G.V., de la Cruz C.C., Chiu C., Alag N., Schaefer G., Crocker L., Ross S., Goldenberg D., Merchant M., Tien J., et al. Blocking NRG1 and other ligand-mediated Her4 signaling enhances the magnitude and duration of the chemotherapeutic response of non-small cell lung cancer. Sci. Transl. Med. 2013, 5:71ra18.
72. Heiser L.M., Sadanandam A., Kuo W.L., Benz S.C., Goldstein T.C., Ng S., Gibb W.J., Wang N.J., Ziyad S., Tong F., et al. Subtype and pathway specific responses to anticancer compounds in breast cancer. Proc. Natl. Acad. Sci. USA 2012, 109:2724-2729.
73. Higginbotham J.N., Demory Beckler M., Gephart J.D., Franklin J.L., Bogatcheva G., Kremers G.J., Piston D.W., Ayers G.D., McConnell R.E., Tyska M.J., Coffey R.J. Amphiregulin exosomes increase cancer cell invasion. Curr. Biol. 2011, 21:779-786.
74. Huang X., Gao L., Wang S., McManaman J.L., Thor A.D., Yang X., Esteva F.J., Liu B. Heterotrimerization of the growth factor receptors erbB2, erbB3, and insulin-like growth factor-i receptor in breast cancer cells resistant to herceptin. Cancer Res. 2010, 70:1204-1214.
75. Hurley J., Doliny P., Reis I., Silva O., Gomez-Fernandez C., Velez P., Pauletti G., Powell J.E., Pegram M.D., Slamon D.J. Docetaxel, cisplatin, and trastuzumab as primary systemic therapy for human epidermal growth factor receptor 2-positive locally advanced breast cancer. J.Clin. Oncol. 2006, 24:1831-1838.
76. Hurvitz S.A., Betting D.J., Stern H.M., Quinaux E., Stinson J., Seshagiri S., Zhao Y., Buyse M., Mackey J., Driga A., et al. Analysis of Fcγ receptor IIIa and IIa polymorphisms: lack of correlation with outcome in trastuzumab-treated breast cancer patients. Clin. Cancer Res. 2012, 18:3478-3486.
77. Hurvitz S.A., Dalenc F., Campone M., O'Regan R.M., Tjan-Heijnen V.C., Gligorov J., Llombart A., Jhangiani H., Mirshahidi H.R., Tan-Chiu E., et al. A phase 2 study of everolimus combined with trastuzumab and paclitaxel in patients with HER2-overexpressing advanced breast cancer that progressed during prior trastuzumab and taxane therapy. Breast Cancer Res. Treat. 2013, 141:437-446.
78. Hynes N.E., MacDonald G. ErbB receptors and signaling pathways in cancer. Curr. Opin. Cell Biol. 2009, 21:177-184.
79. Jaiswal B.S., Kljavin N.M., Stawiski E.W., Chan E., Parikh C., Durinck S., Chaudhuri S., Pujara K., Guillory J., Edgar K.A., et al. Oncogenic ERBB3 mutations in human cancers. Cancer Cell 2013, 23:603-617.
80. Janjigian Y.Y., Groen H.J., Horn L., Smit E.F., Fu Y., Wang F., Shahidi M., Denis L.J., Pao W., Miller V.A. Activity and tolerability of afatinib (BIBW 2992) and cetuximab in NSCLC patients with acquired resistance to erlotinib or gefitinib. J.Clin. Oncol. 2011, 29(Suppl.). abstr. 7525.
81. Ji H., Li D., Chen L., Shimamura T., Kobayashi S., McNamara K., Mahmood U., Mitchell A., Sun Y., Al-Hashem R., et al. The impact of human EGFR kinase domain mutations on lung tumorigenesis and invivo sensitivity to EGFR-targeted therapies. Cancer Cell 2006, 9:485-495.
82. Jonker D.J., O'Callaghan C.J., Karapetis C.S., Zalcberg J.R., Tu D., Au H.J., Berry S.R., Krahn M., Price T., Simes R.J., et al. Cetuximab for the treatment of colorectal cancer. N.Engl. J. Med. 2007, 357:2040-2048.
83. Junttila T.T., Akita R.W., Parsons K., Fields C., Lewis Phillips G.D., Friedman L.S., Sampath D., Sliwkowski M.X. Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941. Cancer Cell 2009, 15:429-440.
84. Junttila T.T., Li G., Parsons K., Phillips G.L., Sliwkowski M.X. Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer. Breast Cancer Res. Treat. 2011, 128:347-356.
85. Katayama R., Shaw A.T., Khan T.M., Mino-Kenudson M., Solomon B.J., Halmos B., Jessop N.A., Wain J.C., Yeo A.T., Benes C., et al. Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers. Sci. Transl. Med. 2012, 4:20ra17.
86. Kawamoto T., Sato J.D., Le A., Polikoff J., Sato G.H., Mendelsohn J. Growth stimulation of A431 cells by epidermal growth factor: identification of high-affinity receptors for epidermal growth factor by an anti-receptor monoclonal antibody. Proc. Natl. Acad. Sci. USA 1983, 80:1337-1341.
87. Khambata-Ford S., Garrett C.R., Meropol N.J., Basik M., Harbison C.T., Wu S., Wong T.W., Huang X., Takimoto C.H., Godwin A.K., et al. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J.Clin. Oncol. 2007, 25:3230-3237.
88. Kobayashi S., Boggon T.J., Dayaram T., Jänne P.A., Kocher O., Meyerson M., Johnson B.E., Eck M.J., Tenen D.G., Halmos B. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N.Engl. J. Med. 2005, 352:786-792.
89. Konecny G.E., Pegram M.D., Venkatesan N., Finn R., Yang G., Rahmeh M., Untch M., Rusnak D.W., Spehar G., Mullin R.J., et al. Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res. 2006, 66:1630-1639.
90. Kwong K.Y., Hung M.C. A novel splice variant of HER2 with increased transformation activity. Mol. Carcinog. 1998, 23:62-68.
91. Lee J.W., Soung Y.H., Seo S.H., Kim S.Y., Park C.H., Wang Y.P., Park K., Nam S.W., Park W.S., Kim S.H., et al. Somatic mutations of ERBB2 kinase domain in gastric, colorectal, and breast carcinomas. Clin. Cancer Res. 2006, 12:57-61.
92. Lee-Hoeflich S.T., Crocker L., Yao E., Pham T., Munroe X., Hoeflich K.P., Sliwkowski M.X., Stern H.M. A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy. Cancer Res. 2008, 68:5878-5887.
93. Lewis Phillips G.D., Li G., Dugger D.L., Crocker L.M., Parsons K.L., Mai E., Blättler W.A., Lambert J.M., Chari R.V., Lutz R.J., et al. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res. 2008, 68:9280-9290.
94. Liang K., Esteva F.J., Albarracin C., Stemke-Hale K., Lu Y., Bianchini G., Yang C.Y., Li Y., Li X., Chen C.T., et al. Recombinant human erythropoietin antagonizes trastuzumab treatment of breast cancer cells via Jak2-mediated Src activation and PTEN inactivation. Cancer Cell 2010, 18:423-435.
95. Licitra L., Mesia R., Rivera F., Remenár E., Hitt R., Erfán J., Rottey S., Kawecki A., Zabolotnyy D., Benasso M., et al. Evaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck: EXTREME study. Ann. Oncol. 2011, 22:1078-1087.
96. Licitra L., Störkel S., Kerr K.M., Van Cutsem E., Pirker R., Hirsch F.R., Vermorken J.B., von Heydebreck A., Esser R., Celik I., Ciardiello F. Predictive value of epidermal growth factor receptor expression for first-line chemotherapy plus cetuximab in patients with head and neck and colorectal cancer: analysis of data from the EXTREME and CRYSTAL studies. Eur. J. Cancer 2013, 49:1161-1168.
97. Liedtke C., Mazouni C., Hess K.R., André F., Tordai A., Mejia J.A., Symmans W.F., Gonzalez-Angulo A.M., Hennessy B., Green M., et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J.Clin. Oncol. 2008, 26:1275-1281.
98. Liu L., Greger J., Shi H., Liu Y., Greshock J., Annan R., Halsey W., Sathe G.M., Martin A.M., Gilmer T.M. Novel mechanism of lapatinib resistance in HER2-positive breast tumor cells: activation of AXL. Cancer Res. 2009, 69:6871-6878.
99. Liu X., Ory V., Chapman S., Yuan H., Albanese C., Kallakury B., Timofeeva O.A., Nealon C., Dakic A., Simic V., et al. ROCK inhibitor and feeder cells induce the conditional reprogramming of epithelial cells. Am. J. Pathol. 2012, 180:599-607.
100. Lynch T.J., Bell D.W., Sordella R., Gurubhagavatula S., Okimoto R.A., Brannigan B.W., Harris P.L., Haserlat S.M., Supko J.G., Haluska F.G., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N.Engl. J. Med. 2004, 350:2129-2139.
101. Maheswaran S., Sequist L.V., Nagrath S., Ulkus L., Brannigan B., Collura C.V., Inserra E., Diederichs S., Iafrate A.J., Bell D.W., et al. Detection of mutations in EGFR in circulating lung-cancer cells. N.Engl. J. Med. 2008, 359:366-377.
102. Mattoon D.R., Lamothe B., Lax I., Schlessinger J. The docking protein Gab1 is the primary mediator of EGF-stimulated activation of the PI-3K/Akt cell survival pathway. BMC Biol. 2004, 2:24.
103. McDermott U., Pusapati R.V., Christensen J.G., Gray N.S., Settleman J. Acquired resistance of non-small cell lung cancer cells to MET kinase inhibition is mediated by a switch to epidermal growth factor receptor dependency. Cancer Res. 2010, 70:1625-1634.
104. McDonagh C.F., Huhalov A., Harms B.D., Adams S., Paragas V., Oyama S., Zhang B., Luus L., Overland R., Nguyen S., et al. Antitumor activity of a novel bispecific antibody that targets the ErbB2/ErbB3 oncogenic unit and inhibits heregulin-induced activation of ErbB3. Mol. Cancer Ther. 2012, 11:582-593.
105. Mellinghoff I.K., Wang M.Y., Vivanco I., Haas-Kogan D.A., Zhu S., Dia E.Q., Lu K.V., Yoshimoto K., Huang J.H., Chute D.J., et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N.Engl. J. Med. 2005, 353:2012-2024.
106. Minkovsky N., Berezov A. BIBW-2992, a dual receptor tyrosine kinase inhibitor for the treatment of solid tumors. Curr. Opin. Investig. Drugs 2008, 9:1336-1346.
107. Minuti G., Cappuzzo F., Duchnowska R., Jassem J., Fabi A., O'Brien T., Mendoza A.D., Landi L., Biernat W., Czartoryska-Arłukowicz B., et al. Increased MET and HGF gene copy numbers are associated with trastuzumab failure in HER2-positive metastatic breast cancer. Br. J. Cancer 2012, 107:793-799.
108. Mirschberger C., Schiller C.B., Schräml M., Dimoudis N., Friess T., Gerdes C.A., Reiff U., Lifke V., Hoelzlwimmer G., Kolm I., et al. RG7116, a therapeutic antibody that binds the inactive HER3 receptor and is optimized for immune effector activation. Cancer Res. 2013, 73:5183-5194.
109. Misale S., Yaeger R., Hobor S., Scala E., Janakiraman M., Liska D., Valtorta E., Schiavo R., Buscarino M., Siravegna G., et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature 2012, 486:532-536.
110. Misale S., Arena S., Lamba S., Siravegna G., Lallo A., Hobor S., Russo M., Buscarino M., Lazzari L., Sartore-Bianchi A., et al. Blockade of EGFR and MEK Intercepts Heterogeneous Mechanisms of Acquired Resistance to Anti-EGFR Therapies in Colorectal Cancer. Sci. Transl. Med. 2014, 6:24ra26.
111. Mitra D., Brumlik M.J., Okamgba S.U., Zhu Y., Duplessis T.T., Parvani J.G., Lesko S.M., Brogi E., Jones F.E. An oncogenic isoform of HER2 associated with locally disseminated breast cancer and trastuzumab resistance. Mol. Cancer Ther. 2009, 8:2152-2162.
112. Mittendorf E.A., Wu Y., Scaltriti M., Meric-Bernstam F., Hunt K.K., Dawood S., Esteva F.J., Buzdar A.U., Chen H., Eksambi S., et al. Loss of HER2 amplification following trastuzumab-based neoadjuvant systemic therapy and survival outcomes. Clin. Cancer Res. 2009, 15:7381-7388.
113. Mok T.S., Wu Y.L., Thongprasert S., Yang C.H., Chu D.T., Saijo N., Sunpaweravong P., Han B., Margono B., Ichinose Y., et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N.Engl. J. Med. 2009, 361:947-957.
114. Molina M.A., Codony-Servat J., Albanell J., Rojo F., Arribas J., Baselga J. Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells. Cancer Res. 2001, 61:4744-4749.
115. Montagut C., Dalmases A., Bellosillo B., Crespo M., Pairet S., Iglesias M., Salido M., Gallen M., Marsters S., Tsai S.P., et al. Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer. Nat. Med. 2012, 18:221-223.
116. Moore M.J., Goldstein D., Hamm J., Figer A., Hecht J.R., Gallinger S., Au H.J., Murawa P., Walde D., Wolff R.A., et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J.Clin. Oncol. 2007, 25:1960-1966. National Cancer Institute of Canada Clinical Trials Group.
117. Moroni M., Veronese S., Benvenuti S., Marrapese G., Sartore-Bianchi A., Di Nicolantonio F., Gambacorta M., Siena S., Bardelli A. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol. 2005, 6:279-286.
118. Morrow P.K., Wulf G.M., Ensor J., Booser D.J., Moore J.A., Flores P.R., Xiong Y., Zhang S., Krop I.E., Winer E.P., et al. Phase I/II study of trastuzumab in combination with everolimus (RAD001) in patients with HER2-overexpressing metastatic breast cancer who progressed on trastuzumab-based therapy. J.Clin. Oncol. 2011, 29:3126-3132.
119. Moscatello D.K., Holgado-Madruga M., Godwin A.K., Ramirez G., Gunn G., Zoltick P.W., Biegel J.A., Hayes R.L., Wong A.J. Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors. Cancer Res. 1995, 55:5536-5539.
120. Muller W.J., Arteaga C.L., Muthuswamy S.K., Siegel P.M., Webster M.A., Cardiff R.D., Meise K.S., Li F., Halter S.A., Coffey R.J. Synergistic interaction of the Neu proto-oncogene product and transforming growth factor alpha in the mammary epithelium of transgenic mice. Mol. Cell. Biol. 1996, 16:5726-5736.
121. Muranen T., Selfors L.M., Worster D.T., Iwanicki M.P., Song L., Morales F.C., Gao S., Mills G.B., Brugge J.S. Inhibition of PI3K/mTOR leads to adaptive resistance in matrix-attached cancer cells. Cancer Cell 2012, 21:227-239.
122. Musolino A., Naldi N., Bortesi B., Pezzuolo D., Capelletti M., Missale G., Laccabue D., Zerbini A., Camisa R., Bisagni G., et al. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J.Clin. Oncol. 2008, 26:1789-1796.
123. Nagata Y., Lan K.H., Zhou X., Tan M., Esteva F.J., Sahin A.A., Klos K.S., Li P., Monia B.P., Nguyen N.T., et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 2004, 6:117-127.
124. Nahta R., Takahashi T., Ueno N.T., Hung M.C., Esteva F.J. P27(kip1) down-regulation is associated with trastuzumab resistance in breast cancer cells. Cancer Res. 2004, 64:3981-3986.
125. Nahta R., Yuan L.X., Zhang B., Kobayashi R., Esteva F.J. Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. Cancer Res. 2005, 65:11118-11128.
126. Nahta R., Yuan L.X., Du Y., Esteva F.J. Lapatinib induces apoptosis in trastuzumab-resistant breast cancer cells: effects on insulin-like growth factor I signaling. Mol. Cancer Ther. 2007, 6:667-674.
127. Ng K.P., Hillmer A.M., Chuah C.T., Juan W.C., Ko T.K., Teo A.S., Ariyaratne P.N., Takahashi N., Sawada K., Fei Y., et al. A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer. Nat. Med. 2012, 18:521-528.
128. Niederst M.J., Engelman J.A. Bypass mechanisms of resistance to receptor tyrosine kinase inhibition in lung cancer. Sci. Signal. 2013, 6:re6.
129. Nishikawa R., Ji X.D., Harmon R.C., Lazar C.S., Gill G.N., Cavenee W.K., Huang H.J. A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity. Proc. Natl. Acad. Sci. USA 1994, 91:7727-7731.
130. O'Brien C., Wallin J.J., Sampath D., GuhaThakurta D., Savage H., Punnoose E.A., Guan J., Berry L., Prior W.W., Amler L.C., et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin. Cancer Res. 2010, 16:3670-3683.
131. O'Regan R., Ozguroglu M., Andre F., Toi M., Jerusalem G., Wilks S., Isaacs C., Xu B., Masuda N., Arena F.P., Yardley D.A., Yap Y.S., Mukhopadhyay P., Douma S., El-Hashimy M., Taran T., Sahmoud T., Lebwohl D.E., Gianni L. Phase III randomized, double-blind, placebo-controlled, multicenter trial of daily everolimus plus weekly trastuzumab and vinorelbine in trastuzumab-resistant, advanced breast cancer (BOLERO-3). J.Clin. Oncol. 2013, 31(Suppl.). abstr. 505.
132. Ohashi K., Sequist L.V., Arcila M.E., Moran T., Chmielecki J., Lin Y.L., Pan Y., Wang L., de Stanchina E., Shien K., et al. Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1. Proc. Natl. Acad. Sci. USA 2012, 109:E2127-E2133.
133. Paez J.G., Jänne P.A., Lee J.C., Tracy S., Greulich H., Gabriel S., Herman P., Kaye F.J., Lindeman N., Boggon T.J., et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004, 304:1497-1500.
134. Paik S., Kim C., Wolmark N. HER2 status and benefit from adjuvant trastuzumab in breast cancer. N.Engl. J. Med. 2008, 358:1409-1411.
135. Pao W., Chmielecki J. Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer. Nat. Rev. Cancer 2010, 10:760-774.
136. Pao W., Miller V., Zakowski M., Doherty J., Politi K., Sarkaria I., Singh B., Heelan R., Rusch V., Fulton L., et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc. Natl. Acad. Sci. USA 2004, 101:13306-13311.
137. Pao W., Miller V.A., Politi K.A., Riely G.J., Somwar R., Zakowski M.F., Kris M.G., Varmus H. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. 2005, 2:e73.
138. Park S., Jiang Z., Mortenson E.D., Deng L., Radkevich-Brown O., Yang X., Sattar H., Wang Y., Brown N.K., Greene M., et al. The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity. Cancer Cell 2010, 18:160-170.
139. Perez E.A., Dueck A.C., McCullough A.E., Chen B., Geiger X.J., Jenkins R.B., Lingle W.L., Davidson N.E., Martino S., Kaufman P.A., et al. Impact of PTEN protein expression on benefit from adjuvant trastuzumab in early-stage human epidermal growth factor receptor 2-positive breast cancer in the North Central Cancer Treatment Group N9831 trial. J.Clin. Oncol. 2013, 31:2115-2122.
140. Phillips G.D., Fields C.T., Li G., Dowbenko D., Schaefer G., Miller K., Andre F., Burris H.A., Albain K.S., Harbeck N., et al. Dual Targeting of HER2-Positive Cancer with Trastuzumab Emtansine and Pertuzumab: Critical Role for Neuregulin Blockade in Antitumor Response to Combination Therapy. Clin. Cancer Res. 2014, 20:456-468.
141. Piccart-Gebhart M.J., Procter M., Leyland-Jones B., Goldhirsch A., Untch M., Smith I., Gianni L., Baselga J., Bell R., Jackisch C., et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N.Engl. J. Med. 2005, 353:1659-1672. Herceptin Adjuvant (HERA) Trial Study Team.
142. Politi K., Zakowski M.F., Fan P.D., Schonfeld E.A., Pao W., Varmus H.E. Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors. Genes Dev. 2006, 20:1496-1510.
143. Prahallad A., Sun C., Huang S., Di Nicolantonio F., Salazar R., Zecchin D., Beijersbergen R.L., Bardelli A., Bernards R. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature 2012, 483:100-103.
144. Price-Schiavi S.A., Jepson S., Li P., Arango M., Rudland P.S., Yee L., Carraway K.L. Rat Muc4 (sialomucin complex) reduces binding of anti-ErbB2 antibodies to tumor cell surfaces, a potential mechanism for herceptin resistance. Int. J. Cancer 2002, 99:783-791.
145. Prickett T.D., Agrawal N.S., Wei X., Yates K.E., Lin J.C., Wunderlich J.R., Cronin J.C., Cruz P., Rosenberg S.A., Samuels Y. Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4. Nat. Genet. 2009, 41:1127-1132.
146. Prowell T.M., Pazdur R. Pathological complete response and accelerated drug approval in early breast cancer. N.Engl. J. Med. 2012, 366:2438-2441.
147. Qi J., McTigue M.A., Rogers A., Lifshits E., Christensen J.G., Jänne P.A., Engelman J.A. Multiple mutations and bypass mechanisms can contribute to development of acquired resistance to MET inhibitors. Cancer Res. 2011, 71:1081-1091.
148. Ranson M., Pao W., Kim D.-W., Kim S.-W., Ohe Y., Felip E., Planchard D., Ghiorghiu S., Cantarini M., Cross D., et al. AZD9291: an irreversible, potent and selective tyrosine kinase inhibitor (TKI) of activating (EGFRm+) and resistance (T790M) mutations in advanced NSCLC. J.Thorac. Oncol. 2013, 8:s389.
149. Regales L., Gong Y., Shen R., de Stanchina E., Vivanco I., Goel A., Koutcher J.A., Spassova M., Ouerfelli O., Mellinghoff I.K., et al. Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer. J.Clin. Invest. 2009, 119:3000-3010.
150. Rexer B.N., Arteaga C.L. Optimal targeting of HER2-PI3K signaling in breast cancer: mechanistic insights and clinical implications. Cancer Res. 2013, 73:3817-3820.
151. Rexer B.N., Ham A.J., Rinehart C., Hill S., Granja-Ingram Nde.M., González-Angulo A.M., Mills G.B., Dave B., Chang J.C., Liebler D.C., Arteaga C.L. Phosphoproteomic mass spectrometry profiling links Src family kinases to escape from HER2 tyrosine kinase inhibition. Oncogene 2011, 30:4163-4174.
152. Rexer B.N., Shyr Y., Arteaga C.L. Phosphatase and tensin homolog deficiency and resistance to trastuzumab and chemotherapy. J.Clin. Oncol. 2013, 31:2073-2075.
153. Ritter C.A., Perez-Torres M., Rinehart C., Guix M., Dugger T., Engelman J.A., Arteaga C.L. Human breast cancer cells selected for resistance to trastuzumab invivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor network. Clin. Cancer Res. 2007, 13:4909-4919.
154. Robert N., Leyland-Jones B., Asmar L., Belt R., Ilegbodu D., Loesch D., Raju R., Valentine E., Sayre R., Cobleigh M., et al. Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer. J.Clin. Oncol. 2006, 24:2786-2792.
155. Romond E.H., Perez E.A., Bryant J., Suman V.J., Geyer C.E., Davidson N.E., Tan-Chiu E., Martino S., Paik S., Kaufman P.A., et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N.Engl. J. Med. 2005, 353:1673-1684.
156. Rosell R., Molina M.A., Costa C., Simonetti S., Gimenez-Capitan A., Bertran-Alamillo J., Mayo C., Moran T., Mendez P., Cardenal F., et al. Pretreatment EGFR T790M mutation and BRCA1 mRNA expression in erlotinib-treated advanced non-small-cell lung cancer patients with EGFR mutations. Clin. Cancer Res. 2011, 17:1160-1168.
157. Rosell R., Carcereny E., Gervais R., Vergnenegre A., Massuti B., Felip E., Palmero R., Garcia-Gomez R., Pallares C., Sanchez J.M., et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012, 13:239-246. Spanish Lung Cancer Group in collaboration with Groupe Français de Pneumo-Cancérologie and Associazione Italiana Oncologia Toracica.
158. Ross J.S., Wang K., Sheehan C.E., Boguniewicz A.B., Otto G., Downing S.R., Sun J., He J., Curran J.A., Ali S., et al. Relapsed classic E-cadherin (CDH1)-mutated invasive lobular breast cancer shows a high frequency of HER2 (ERBB2) gene mutations. Clin. Cancer Res. 2013, 19:2668-2676.
159. Rubin Grandis J., Melhem M.F., Gooding W.E., Day R., Holst V.A., Wagener M.M., Drenning S.D., Tweardy D.J. Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. J.Natl. Cancer Inst. 1998, 90:824-832.
160. Sasaki T., Koivunen J., Ogino A., Yanagita M., Nikiforow S., Zheng W., Lathan C., Marcoux J.P., Du J., Okuda K., et al. A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors. Cancer Res. 2011, 71:6051-6060.
161. Scaltriti M., Rojo F., Ocaña A., Anido J., Guzman M., Cortes J., Di Cosimo S., Matias-Guiu X., Ramon y Cajal S., Arribas J., Baselga J. Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. J.Natl. Cancer Inst. 2007, 99:628-638.
162. Scaltriti M., Verma C., Guzman M., Jimenez J., Parra J.L., Pedersen K., Smith D.J., Landolfi S., Ramon y Cajal S., Arribas J., Baselga J. Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity. Oncogene 2009, 28:803-814.
163. Scaltriti M., Chandarlapaty S., Prudkin L., Aura C., Jimenez J., Angelini P.D., Sánchez G., Guzman M., Parra J.L., Ellis C., et al. Clinical benefit of lapatinib-based therapy in patients with human epidermal growth factor receptor 2-positive breast tumors coexpressing the truncated p95HER2 receptor. Clin. Cancer Res. 2010, 16:2688-2695.
164. Scaltriti M., Eichhorn P.J., Cortés J., Prudkin L., Aura C., Jiménez J., Chandarlapaty S., Serra V., Prat A., Ibrahim Y.H., et al. Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2+ breast cancer patients. Proc. Natl. Acad. Sci. USA 2011, 108:3761-3766.
165. Schaefer G., Haber L., Crocker L.M., Shia S., Shao L., Dowbenko D., Totpal K., Wong A., Lee C.V., Stawicki S., et al. A two-in-one antibody against HER3 and EGFR has superior inhibitory activity compared with monospecific antibodies. Cancer Cell 2011, 20:472-486.
166. Schechter A.L., Stern D.F., Vaidyanathan L., Decker S.J., Drebin J.A., Greene M.I., Weinberg R.A. The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen. Nature 1984, 312:513-516.
167. Scheuer W., Friess T., Burtscher H., Bossenmaier B., Endl J., Hasmann M. Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models. Cancer Res. 2009, 69:9330-9336.
168. Schneeweiss A., Chia S., Hickish T., Harvey V., Eniu A., Hegg R., Tausch C., Seo J.H., Tsai Y.F., Ratnayake J., et al. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Ann. Oncol. 2013, 24:2278-2284.
169. Schoeberl B., Faber A.C., Li D., Liang M.C., Crosby K., Onsum M., Burenkova O., Pace E., Walton Z., Nie L., et al. An ErbB3 antibody, MM-121, is active in cancers with ligand-dependent activation. Cancer Res. 2010, 70:2485-2494.
170. Sequist L.V., Waltman B.A., Dias-Santagata D., Digumarthy S., Turke A.B., Fidias P., Bergethon K., Shaw A.T., Gettinger S., Cosper A.K., et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci. Transl. Med. 2011, 3:75ra26.
171. Sequist L.V., Soria J.-C., Gadgeel S.M., Wakelee H.A., Camidge D.R., Varga A., Fidias P., Wozniak A.J., Neal J.W., Doebele R.C., et al. First-in-human evaluation of CO-1686, an irreversible, selective, and potent tyrosine kinase inhibitor of EGFR T790M. J.Clin. Oncol. 2013, 31(Suppl.). abstr. 2524.
172. Sequist L.V., Yang J.C., Yamamoto N., O'Byrne K., Hirsh V., Mok T., Geater S.L., Orlov S., Tsai C.M., Boyer M., et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J.Clin. Oncol. 2013, 31:3327-3334.
173. Serra V., Markman B., Scaltriti M., Eichhorn P.J., Valero V., Guzman M., Botero M.L., Llonch E., Atzori F., Di Cosimo S., et al. NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. Cancer Res. 2008, 68:8022-8030.
174. Sharma S.V., Lee D.Y., Li B., Quinlan M.P., Takahashi F., Maheswaran S., McDermott U., Azizian N., Zou L., Fischbach M.A., et al. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell 2010, 141:69-80.
175. Shattuck D.L., Miller J.K., Carraway K.L., Sweeney C. Met receptor contributes to trastuzumab resistance of Her2-overexpressing breast cancer cells. Cancer Res. 2008, 68:1471-1477.
176. Sheng Q., Liu X., Fleming E., Yuan K., Piao H., Chen J., Moustafa Z., Thomas R.K., Greulich H., Schinzel A., et al. An activated ErbB3/NRG1 autocrine loop supports invivo proliferation in ovarian cancer cells. Cancer Cell 2010, 17:298-310.
177. Shepherd F.A., Rodrigues Pereira J., Ciuleanu T., Tan E.H., Hirsh V., Thongprasert S., Campos D., Maoleekoonpiroj S., Smylie M., Martins R., et al. Erlotinib in previously treated non-small-cell lung cancer. N.Engl. J. Med. 2005, 353:123-132. National Cancer Institute of Canada Clinical Trials Group.
178. Shi F., Telesco S.E., Liu Y., Radhakrishnan R., Lemmon M.A. ErbB3/HER3 intracellular domain is competent to bind ATP and catalyze autophosphorylation. Proc. Natl. Acad. Sci. USA 2010, 107:7692-7697.
179. Singh B., Coffey R.J. Trafficking of epidermal growth factor receptor ligands in polarized epithelial cells. Annu. Rev. Physiol. 2014, 76:275-300.
180. Singh B., Bogatcheva G., Washington M.K., Coffey R.J. Transformation of polarized epithelial cells by apical mistrafficking of epiregulin. Proc. Natl. Acad. Sci. USA 2013, 110:8960-8965.
181. Slamon D.J., Clark G.M., Wong S.G., Levin W.J., Ullrich A., McGuire W.L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987, 235:177-182.
182. Slamon D.J., Leyland-Jones B., Shak S., Fuchs H., Paton V., Bajamonde A., Fleming T., Eiermann W., Wolter J., Pegram M., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N.Engl. J. Med. 2001, 344:783-792.
183. Soria J.-C., Sequist L.V., Gadgeel S., Goldman J., Wakelee H., Varga A., Fidias P., Wozniak A.J., Neal J.W., Doebele R.C., et al. First-in-human evaluation of CO-1686, an irreversible, highly selective tyrosine kinase inhibitor of mutations of EGFR (activating and T790M). J.Thorac. Oncol. 2013, 8:s141.
184. Sos M.L., Koker M., Weir B.A., Heynck S., Rabinovsky R., Zander T., Seeger J.M., Weiss J., Fischer F., Frommolt P., et al. PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR. Cancer Res. 2009, 69:3256-3261.
185. Stagg J., Loi S., Divisekera U., Ngiow S.F., Duret H., Yagita H., Teng M.W., Smyth M.J. Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy. Proc. Natl. Acad. Sci. USA 2011, 108:7142-7147.
186. Stephens P., Hunter C., Bignell G., Edkins S., Davies H., Teague J., Stevens C., O'Meara S., Smith R., Parker A., et al. Lung cancer: intragenic ERBB2 kinase mutations in tumours. Nature 2004, 431:525-526.
187. Sugawa N., Ekstrand A.J., James C.D., Collins V.P. Identical splicing of aberrant epidermal growth factor receptor transcripts from amplified rearranged genes in human glioblastomas. Proc. Natl. Acad. Sci. USA 1990, 87:8602-8606.
188. Takezawa K., Pirazzoli V., Arcila M.E., Nebhan C.A., Song X., de Stanchina E., Ohashi K., Janjigian Y.Y., Spitzler P.J., Melnick M.A., et al. HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation. Cancer Discov. 2012, 2:922-933.
189. Tanizaki J., Okamoto I., Fumita S., Okamoto W., Nishio K., Nakagawa K. Roles of BIM induction and survivin downregulation in lapatinib-induced apoptosis in breast cancer cells with HER2 amplification. Oncogene 2011, 30:4097-4106.
190. Turke A.B., Zejnullahu K., Wu Y.L., Song Y., Dias-Santagata D., Lifshits E., Toschi L., Rogers A., Mok T., Sequist L., et al. Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell 2010, 17:77-88.
191. Turke A.B., Song Y., Costa C., Cook R., Arteaga C.L., Asara J.M., Engelman J.A. MEK inhibition leads to PI3K/AKT activation by relieving a negative feedback on ERBB receptors. Cancer Res. 2012, 72:3228-3237.
192. Utermark T., Rao T., Cheng H., Wang Q., Lee S.H., Wang Z.C., Iglehart J.D., Roberts T.M., Muller W.J., Zhao J.J. The p110α and p110β isoforms of PI3K play divergent roles in mammary gland development and tumorigenesis. Genes Dev. 2012, 26:1573-1586.
193. Van Cutsem E., Peeters M., Siena S., Humblet Y., Hendlisz A., Neyns B., Canon J.L., Van Laethem J.L., Maurel J., Richardson G., et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J.Clin. Oncol. 2007, 25:1658-1664.
194. Van Cutsem E., Köhne C.H., Hitre E., Zaluski J., Chang Chien C.R., Makhson A., D'Haens G., Pintér T., Lim R., Bodoky G., et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N.Engl. J. Med. 2009, 360:1408-1417.
195. Vaught D.B., Stanford J.C., Young C., Hicks D.J., Wheeler F., Rinehart C., Sánchez V., Koland J., Muller W.J., Arteaga C.L., Cook R.S. HER3 is required for HER2-induced preneoplastic changes to the breast epithelium and tumor formation. Cancer Res. 2012, 72:2672-2682.
196. Verma S., Miles D., Gianni L., Krop I.E., Welslau M., Baselga J., Pegram M., Oh D.Y., Diéras V., Guardino E., et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N.Engl. J. Med. 2012, 367:1783-1791. EMILIA Study Group.
197. Vermorken J.B., Mesia R., Rivera F., Remenar E., Kawecki A., Rottey S., Erfan J., Zabolotnyy D., Kienzer H.R., Cupissol D., et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N.Engl. J. Med. 2008, 359:1116-1127.
198. von Minckwitz G., du Bois A., Schmidt M., Maass N., Cufer T., de Jongh F.E., Maartense E., Zielinski C., Kaufmann M., Bauer W., et al. Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study. J.Clin. Oncol. 2009, 27:1999-2006.
199. Walter A.O., Sjin R.T., Haringsma H.J., Ohashi K., Sun J., Lee K., Dubrovskiy A., Labenski M., Zhu Z., Wang Z., et al. Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC. Cancer Discov. 2013, 3:1404-1415.
200. Wang S.E., Narasanna A., Perez-Torres M., Xiang B., Wu F.Y., Yang S., Carpenter G., Gazdar A.F., Muthuswamy S.K., Arteaga C.L. HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors. Cancer Cell 2006, 10:25-38.
201. Wang S.E., Xiang B., Guix M., Olivares M.G., Parker J., Chung C.H., Pandiella A., Arteaga C.L. Transforming growth factor beta engages TACE and ErbB3 to activate phosphatidylinositol-3 kinase/Akt in ErbB2-overexpressing breast cancer and desensitizes cells to trastuzumab. Mol. Cell. Biol. 2008, 28:5605-5620.
202. Willmore-Payne C., Holden J.A., Layfield L.J. Detection of EGFR- and HER2-activating mutations in squamous cell carcinoma involving the head and neck. Mod. Pathol. 2006, 19:634-640.
203. Wilson T.R., Lee D.Y., Berry L., Shames D.S., Settleman J. Neuregulin-1-mediated autocrine signaling underlies sensitivity to HER2 kinase inhibitors in a subset of human cancers. Cancer Cell 2011, 20:158-172.
204. Wilson T.R., Fridlyand J., Yan Y., Penuel E., Burton L., Chan E., Peng J., Lin E., Wang Y., Sosman J., et al. Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature 2012, 487:505-509.
205. Wood E.R., Truesdale A.T., McDonald O.B., Yuan D., Hassell A., Dickerson S.H., Ellis B., Pennisi C., Horne E., Lackey K., et al. A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells. Cancer Res. 2004, 64:6652-6659.
206. Xia W., Bacus S., Hegde P., Husain I., Strum J., Liu L., Paulazzo G., Lyass L., Trusk P., Hill J., et al. A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer. Proc. Natl. Acad. Sci. USA 2006, 103:7795-7800.
207. Yakes F.M., Chinratanalab W., Ritter C.A., King W., Seelig S., Arteaga C.L. Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action. Cancer Res. 2002, 62:4132-4141.
208. Yano S., Wang W., Li Q., Matsumoto K., Sakurama H., Nakamura T., Ogino H., Kakiuchi S., Hanibuchi M., Nishioka Y., et al. Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations. Cancer Res. 2008, 68:9479-9487.
209. Yano S., Yamada T., Takeuchi S., Tachibana K., Minami Y., Yatabe Y., Mitsudomi T., Tanaka H., Kimura T., Kudoh S., et al. Hepatocyte growth factor expression in EGFR mutant lung cancer with intrinsic and acquired resistance to tyrosine kinase inhibitors in a Japanese cohort. J.Thorac. Oncol. 2011, 6:2011-2017.
210. Yarden Y., Pines G. The ERBB network: at last, cancer therapy meets systems biology. Nat. Rev. Cancer 2012, 12:553-563.
211. Yarden Y., Sliwkowski M.X. Untangling the ErbB signalling network. Nat. Rev. Mol. Cell Biol. 2001, 2:127-137.
212. Yasuda H., Park E., Yun C.H., Sng N.J., Lucena-Araujo A.R., Yeo W.L., Huberman M.S., Cohen D.W., Nakayama S., Ishioka K., et al. Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer. Sci. Transl. Med. 2013, 5:ra177.
213. Yonesaka K., Zejnullahu K., Okamoto I., Satoh T., Cappuzzo F., Souglakos J., Ercan D., Rogers A., Roncalli M., Takeda M., et al. Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab. Sci. Transl. Med. 2011, 3:99ra86.
214. Yu H.A., Arcila M.E., Rekhtman N., Sima C.S., Zakowski M.F., Pao W., Kris M.G., Miller V.A., Ladanyi M., Riely G.J. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin. Cancer Res. 2013, 19:2240-2247.
215. Yun C.H., Boggon T.J., Li Y., Woo M.S., Greulich H., Meyerson M., Eck M.J. Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity. Cancer Cell 2007, 11:217-227.
216. Yun C.H., Mengwasser K.E., Toms A.V., Woo M.S., Greulich H., Wong K.K., Meyerson M., Eck M.J. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc. Natl. Acad. Sci. USA 2008, 105:2070-2075.
217. Zhang S., Huang W.C., Li P., Guo H., Poh S.B., Brady S.W., Xiong Y., Tseng L.M., Li S.H., Ding Z., et al. Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways. Nat. Med. 2011, 17:461-469.
218. Zhang Z., Lee J.C., Lin L., Olivas V., Au V., LaFramboise T., Abdel-Rahman M., Wang X., Levine A.D., Rho J.K., et al. Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer. Nat. Genet. 2012, 44:852-860.
219. Zhou B.B., Peyton M., He B., Liu C., Girard L., Caudler E., Lo Y., Baribaud F., Mikami I., Reguart N., et al. Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer. Cancer Cell 2006, 10:39-50.
220. Zhou W., Ercan D., Chen L., Yun C.H., Li D., Capelletti M., Cortot A.B., Chirieac L., Iacob R.E., Padera R., et al. Novel mutant-selective EGFR kinase inhibitors against EGFR T790M. Nature 2009, 462:1070-1074.
221. Zhuang G., Brantley-Sieders D.M., Vaught D., Yu J., Xie L., Wells S., Jackson D., Muraoka-Cook R., Arteaga C., Chen J. Elevation of receptor tyrosine kinase EphA2 mediates resistance to trastuzumab therapy. Cancer Res. 2010, 70:299-308.
222. Zito C.I., Riches D., Kolmakova J., Simons J., Egholm M., Stern D.F. Direct resequencing of the complete ERBB2 coding sequence reveals an absence of activating mutations in ERBB2 amplified breast cancer. Genes Chromosomes Cancer 2008, 47:633-638.